Apitegromab

Apitegromab (research designation SRK-015) is a fully human monoclonal antibody developed by Scholar Rock that selectively binds and inhibits the activation of pro- and latent forms of myostatin in skeletal muscle. Unlike most myostatin inhibitors that target active myostatin or the activin receptor type IIB, apitegromab targets the inactive precursor forms before they are converted to active myostatin. This selective targeting reduces off-target effects on related TGF-β superfamily members. It is administered as intravenous infusion every four weeks at 10 mg/kg or 20 mg/kg.

The therapeutic rationale is that pro-myostatin and latent myostatin are the substrates from which active myostatin is generated through proteolytic cleavage. Blocking this conversion step reduces functional myostatin without binding to related growth factors (activins, GDF-11).

SMA as the lead indication. Spinal muscular atrophy is a genetic disorder characterized by motor neuron loss and progressive muscle weakness. Approved SMA therapies (nusinersen, risdiplam, onasemnogene abeparvovec) target the underlying SMN protein deficiency. Even with these therapies, substantial motor function deficits persist. Apitegromab adds a muscle-targeted approach that complements rather than replaces SMN-targeted therapy.

FDA designations. Fast Track, Orphan Drug, and Rare Pediatric Disease designations have been granted. The Rare Pediatric Disease designation would qualify Scholar Rock for a Priority Review Voucher upon approval.

Apitegromab acts on pro-myostatin and latent myostatin through highly selective antibody binding.

Myostatin biology. Myostatin (GDF-8) is a TGF-β superfamily member produced primarily by skeletal muscle cells. It normally limits muscle growth through binding to activin type II receptors. Mice lacking myostatin develop substantially increased muscle mass.

Pro- and latent myostatin forms. Myostatin is synthesized as a precursor (pro-myostatin) that requires proteolytic processing to release active myostatin. Latent myostatin is an intermediate form that is also inactive but can be activated by tissue proteases.

Selective targeting. Apitegromab binds the pro- and latent forms with high affinity but does not bind active myostatin or related TGF-β superfamily members. The structural basis was characterized in Dagbay et al. (2020) Journal of Biological Chemistry, showing how SRK-015 recognizes a conformational epitope present in the inactive forms but absent in active myostatin.

Selectivity advantage over earlier myostatin inhibitors. Earlier inhibitors (landogrozumab, domagrozumab, bimagrumab) bound active myostatin or the activin receptor and produced off-target effects through related growth factors. Apitegromab's selectivity for the inactive precursor forms reduces these off-target concerns.

The Phase 3 SAPPHIRE Evidence

Trial design. Randomized, double-blind, placebo-controlled, multicenter Phase 3 trial at 48 hospitals across 9 countries. 156 patients aged 2 to 21 years with nonambulatory type 2 or type 3 SMA receiving nusinersen or risdiplam as standard of care. Randomization to apitegromab 10 mg/kg, 20 mg/kg, or placebo every four weeks for 52 weeks.

Primary endpoint. Change from baseline on HFMSE in the main efficacy population aged 2 to 12 years.

Primary result. Mean difference of 1.8 points (p = 0.019) for all patients aged 2 to 21 years receiving apitegromab combined (n = 106) compared with placebo (n = 50). The trial met its primary endpoint with statistical significance.

Biomarker confirmation. Latent myostatin levels increased in treated patients (because the antibody binds and stabilizes the inactive form), confirming target engagement as designed.

The SAPPHIRE result built on the earlier Phase 2 TOPAZ trial (Neurology, 2024), which provided the initial proof-of-concept in SMA.

Regulatory Status

United States. BLA submitted following SAPPHIRE positive data. FDA Complete Response Letter issued in 2025 citing manufacturing concerns at third-party facility. Resubmission planned after FDA confirms remediation. The clinical data package is intact.

FDA designations. Fast Track, Orphan Drug, and Rare Pediatric Disease.

EU. EMA submission anticipated to follow FDA approval.

WADA status. Not currently named on the WADA Prohibited List. Would fall under section S4.4 (Agents Affecting Myostatin Function) by analogy. Use in competitive sport would be a doping violation.

Phase 3 SAPPHIRE dosing. Apitegromab 10 mg/kg or 20 mg/kg intravenously every four weeks for 52 weeks. The least squares mean difference between apitegromab 20 mg/kg and placebo alone was not significant, suggesting the combined-dose effect was driven primarily by the 10 mg/kg arm.

Earlier Phase 2 TOPAZ trial established the dose range. Patients aged 5 to 21 years with SMA types 2 and 3 received apitegromab 2 mg/kg, 20 mg/kg, or placebo intravenously every four weeks. The dose-response in TOPAZ supported selection of 10 and 20 mg/kg for SAPPHIRE.

Pharmacokinetics. Standard IgG4 antibody half-life (approximately 20 to 25 days) supports every-four-week dosing. Pharmacodynamic biomarker measurements (latent myostatin levels) confirm sustained target engagement throughout the dosing interval.

No FDA approval yet. The BLA dosing recommendation will depend on the labeled dose at approval. Scholar Rock has not publicly disclosed which dose will be on the proposed label.

The SAPPHIRE and TOPAZ safety profiles have been generally well-tolerated in the SMA patient population.

No new safety concerns. The CRL specifically did not cite safety concerns. The Phase 3 safety profile was consistent with the Phase 2 TOPAZ findings.

Common adverse events. Fall, fever, upper respiratory infection, headache, vomiting, and nasopharyngitis. Many of these reflect the underlying SMA disease state (falls in nonambulatory patients, infections in immunocompromised pediatric patients).

Serious adverse events. Pneumonia and dehydration were the most common serious adverse events in pediatric patients aged 2-12 years. These reflect medical vulnerability of severely affected SMA patients rather than apitegromab-specific toxicity.

Selectivity advantage. Targeting pro- and latent myostatin (rather than active myostatin or activin receptors) reduces theoretical off-target concerns including cardiac, vascular, and broader endocrine effects that earlier myostatin inhibitors raised.

No tumorigenic signals. The cytoprotective and growth-supportive mechanism on muscle does not appear to produce off-target neoplastic effects.

Apitegromab (Scholar Rock). Selective antibody against pro/latent myostatin. Phase 3 SAPPHIRE positive in SMA. BLA submitted, CRL issued for manufacturing only.

Landogrozumab, domagrozumab, trevogrumab. Earlier myostatin antibodies (Eli Lilly, Pfizer, Regeneron). Mixed Phase 2/3 results. None FDA-approved.

Bimagrumab. Antibody against activin receptor (ActRII). Phase 2 in sarcopenia and inclusion body myositis. Now being developed for obesity by Versanis (Eli Lilly).

Follistatin gene therapy. AAV-delivered follistatin (natural myostatin antagonist). Phase 1/2a positive in Becker muscular dystrophy. No FDA approval yet.

For SMA specifically, apitegromab is the leading muscle-targeted candidate. The selectivity for pro/latent myostatin is the key differentiation from earlier antibodies. Whether apitegromab receives FDA approval after CRL resolution will define the first commercial entry of muscle-targeted SMA pharmacotherapy.